Fiche publication
Date publication
novembre 2016
Journal
Clinical pharmacokinetics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Pr BOUCHE Olivier
Tous les auteurs :
Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D
Lien Pubmed
Résumé
Clinical response to bevacizumab varies between patients treated for metastatic colorectal cancer (mCRC). The aim of this study was to quantify individual factors affecting bevacizumab pharmacokinetic variability and assess the relationship between bevacizumab concentrations and clinical outcomes.
Mots clés
Aged, Angiogenesis Inhibitors, pharmacokinetics, Bevacizumab, pharmacokinetics, Carcinoembryonic Antigen, metabolism, Colorectal Neoplasms, drug therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Liver Neoplasms, secondary, Male, Middle Aged, Models, Biological, Polymorphism, Genetic, Vascular Endothelial Growth Factor A, metabolism
Référence
Clin Pharmacokinet. 2016 Nov;55(11):1381-1394
